KMPHARMACEUTICAL Co., Ltd.

As of June 30, 2026, KMPHARMACEUTICAL Co., Ltd. carries a market capitalization of 10.31B, placing it among publicly traded companies globally. Its enterprise value stands at 28.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, KMPHARMACEUTICAL Co., Ltd. has 5.58M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.61, and the price-to-book ratio stands at 0.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 28.84B versus a market cap of 10.31B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, KMPHARMACEUTICAL Co., Ltd. maintains a current ratio of 0.28, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 70.00, indicating elevated leverage, while an interest coverage ratio of -4.16 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, KMPHARMACEUTICAL Co., Ltd. posted a negative return on equity (ROE) of -13.12, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.90, reflecting losses generated across the asset base. The company generates approximately 273.79M in revenue per employee across its workforce of 62.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.52 indicates how many times KMPHARMACEUTICAL Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 14, 2026, KMPHARMACEUTICAL Co., Ltd.'s stock has declined approximately 78.52% over the past 52 weeks. The 50-day moving average sits at 1,397.86, while the 200-day moving average is 2,334.57.

Over the twelve months ended June 30, 2026, KMPHARMACEUTICAL Co., Ltd. generated 16.98B in revenue and converted that into -3.77B in net income, yielding earnings per share of -676.55. EBITDA reached -2.01B, while operating income came in at -2.90B.

As of June 30, 2026, KMPHARMACEUTICAL Co., Ltd. holds 138.40M in cash and equivalents against 18.67B in total debt, resulting in a net debt position of 18.53B. Total book value stands at 26.67B, with working capital of -11.45B providing operational flexibility.

KMPHARMACEUTICAL Co., Ltd. produced -2.58B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.25B in capital expenditures, free cash flow totaled -3.83B - equivalent to -686.58 per share.

Over the twelve months ended June 30, 2026, KMPHARMACEUTICAL Co., Ltd. posted a gross margin of 22.25, reflecting its pricing power and cost economics. The operating margin of -17.11 and net profit margin of -22.22 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -37.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.19, meaning KMPHARMACEUTICAL Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

KMPHARMACEUTICAL Co., Ltd.'s most recent stock split took place on May 19, 2026 with a 5:1 split ratio.

As of June 30, 2026, KMPHARMACEUTICAL Co., Ltd. has an Altman Z-Score of 0.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.